Table 2.
Base-case analysis of cost-effectiveness over 10 years for 2 groups
| Variable | First-line of IB group | First-line of BE plus RI group | Incremental (vs. First-line of IB group) |
|---|---|---|---|
| No. of QALYs gained | 4.48 | 3.30 | -1.17 |
| Costs, $a | |||
| Costs of drugs | |||
| Costs of first-line drugs | 172,897.84 | 237,779.12 | 64,881.27 |
| Costs of subsequent drugs | 6,529.77 | 22,455.00 | 15,925.23 |
| Costs of AEs | 229.26 | 66.27 | -163.00 |
| Other Costs | 4,384.66 | 11,787.93 | 7,403.27 |
| Total costs, $ | 184,041.53 | 272,088.31 | 88,046.78 |
| ICERs, $ per QALY | – | – | -75,107.35 |
| Dominance | Absolute dominated | – | – |
Abbreviations: IB, ibrutinib; BE, bendamustine; RI, rituximab; QALYs, quality-adjusted life-years; AEs, adverse events; ICERs, incremental cost-effectiveness ratios
aCosts are estimated in 2022 US dollars